Abstract

Urinary excretion level of 5-S-cysteinyldopa (5-S-CD) has been used as a biochemical marker of efficacy of therapy in malignant melanoma.
We reported a case of 53 year-old female with multiple metastatic melanoma treated with interferon-β-DAV combination therapy. Before treatment, urinary excretion level of 5-S-CD was 1093.2μg/day and its level decreased after a each single course of the treatment and increased thereafter.
The level decreased gradually over the course of the treatment and further decreased to the minimum level, 77.5μg/day after the surgical resection of the tumors.
Our case supported the usefulness of urinary excretion level of 5-S-CD as a marker for monitorring the disease activity of malignant melanoma.